Open November ’12

Title: A Phase 3 randomized study to assess the efficacy and safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib.

Population: Patients who received 1 – 4 prior treatments and are not refractory to Bortezomib (No disease progression within 60 days of Bortezomib treatment).

Resource Links:

« Back